JOSEPH D. MCCRACKEN
This content is PDF only. Please click on the PDF icon to access.
To the editor: Johnson and colleagues (1) pointed out, in their recent review article, the indications and contraindications of immunosuppressive therapy for the treatment of rheumatoid arthritis. They also cited the eight protective guidelines of Schwartz and Gowans (2) for placing a patient on such therapy. The hazard of activating cancer in the immunosuppressed patient is only partially mentioned. Activation of cancer by placing a patient on immunosuppressive therapy is a well-recognized risk (3). This case is a tragic example:
A 45-year-old woman had had previous surgery of the lower back in May of 1970, with removal of a malignant
MCCRACKEN JD. Additional Risk from Immunosuppressive Therapy for Rheumatoid Arthritis. Ann Intern Med. 1973;79:611–612. doi: https://doi.org/10.7326/0003-4819-79-4-611
Download citation file:
Published: Ann Intern Med. 1973;79(4):611-612.
Rheumatoid Arthritis, Rheumatology.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use